How protein metabolism is perturbed during chronic glucocorticoid excess is poorly understood. The aims were to investigate the impact of chronic glucocorticoid excess and restoration of eucortisolemia in Cushing's syndrome (CS) on whole body protein metabolism.
INTRODUCTION
Maintenance of optimal body protein status is an essential regulatory process for health.
Protein loss causes substantial morbidity and increases mortality in chronic renal failure (31), acquired immunodeficiency syndrome (21) and chronic obstructive pulmonary disease (26).
Protein mass is reduced in Cushing's syndrome (3, 9, 49) resulting in skin thinning, muscle wasting and weakness (36) . Protein wasting may contribute directly or indirectly to the markedly increased mortality in untreated Cushing's syndrome (34) .
Body protein is constantly turned over, a process regulated by genetic, nutritional, behavioral, environmental and hormonal factors. Steady-state tracer methodology, such as the leucine turnover technique, has allowed accurate and non-invasive estimation of whole body rates of the 3 main components of protein metabolism: breakdown, oxidation and synthesis. Protein mass is lost when the rate of protein breakdown is increased relative to synthesis or conversely if synthesis is reduced relative to breakdown. Both scenarios result in an increase in irreversible loss of amino acids by oxidation.
The acute impact of pharmacological doses of glucocorticoids on whole body protein metabolism have been well characterized; they increase protein breakdown relative to synthesis, thereby increasing protein oxidation (1, 10, 17) . The impact of chronic glucocorticoid exposure on protein metabolism is controversial. This has been explored in Cushing's syndrome, where protein breakdown and synthesis have been reported to be proportionately reduced (2) or not different to normal subjects (44). In both studies the rate of protein oxidation was similar to normal subjects (2, 44) , an observation which is not consistent with the progressive protein loss that occurs in this condition. Cushing's syndrome is associated with severe perturbations of body composition (3, 9, 49) . Both lean body mass (16, 51) and fat mass (FM) (46) influence rates of whole body protein metabolism.
The above studies did not take into account the confounding effects of abnormal body composition (2, 44) , thus the status of protein metabolism in Cushing's syndrome remains to be clarified.
The aim of this study was to assess the impact of chronic glucocorticoid excess and restoration of eucortisolemia on whole body protein metabolism after accounting for body composition differences in Cushing's syndrome. With this in mind we have undertaken two studies. First, a cross-sectional study compared whole body protein metabolism in subjects with Cushing's syndrome to normal subjects matched for gender, age and weight and secondly, a longitudinal study assessed the impact of restoring eucortisolaemia in subjects with Cushing's syndrome.
MATERIALS AND METHODS

Subjects
Eighteen subjects (12 women) with active Cushing's syndrome were recruited through the St Vincent's Hospital, Department of Endocrinology and 18 normal subjects (11 women) were recruited from the general population. The clinical characteristics of the group of subjects with Cushing's syndrome participating in the cross-sectional study have been previously reported (3). The cause of Cushing's syndrome was an ACTH-producing pituitary tumor in 15 subjects, bilateral micronodular adrenal hyperplasia in one subject, an adrenal adenoma in one subject and ectopic ACTH secretion from a thymic carcinoid tumor in one subject. All subjects with Cushing's syndrome had active disease as defined by an elevated 24-hour urinary free cortisol (mean = 1408±333 nmol/d, normal < 300 nmol/d). The mean duration of symptoms consistent with Cushing's syndrome was 42±9 months. In 12 subjects, Cushing's syndrome was newly diagnosed and these subjects were assessed prior to replacement of other pituitary hormone deficits (which were only present in two subjects). Central hypothyroidism was present in one subject and testosterone was below the lower limit of normal in one male subject. In 6 subjects (4 women), Cushing's disease was persistent following transsphenoidal surgery, with one subject also previously receiving radiotherapy.
These subjects were receiving replacement for other pituitary hormone deficits as appropriate including thyroxine replacement (n=3), with one male subject receiving testosterone replacement.
10 subjects with Cushing's syndrome were restudied on a second occasion, 13.6±2.4 months after their initial study, following successful treatment of Cushing's syndrome. Treatment consisted of a transsphenoidal hypophysectomy (n=6), bilateral adrenalectomy (n=1), stereotactic pituitary radiotherapy (n=2) and a transsphenoidal hypophysectomy followed by bilateral adrenalectomy (n=1). Five subjects were on no glucocorticoid replacement with a normal 24-h urinary free cortisol and 5 subjects were receiving physiologic glucocorticoid replacement. Post-operatively, two subjects developed central hypothyroidism. Both received physiologic replacement therapy (thyroxine 100 µg/d) for at least 6 months before the second study. The Research Ethics Committee of St Vincent's Hospital (Sydney, Australia) approved both studies and all subjects provided written informed consent.
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Experimental Protocol
Subjects attended the Clinical Research Facility, Garvan Institute of Medical Research at 08.30 hours after an overnight fast, where they underwent assessment of whole-body protein metabolism and body composition.
Body composition: Body composition was assessed by dual energy x-ray absorptiometry (DXA) using a 3-compartment model; FM, LBM and bone mineral content (BMC) were measured using a total body scanner (Lunar model DPX, software version 3.1, Lunar Corp., Madison, WI), which also quantified regional body composition of upper and lower limb along with truncal fat. Truncal fat comprises fat in the chest, abdominal and pelvic regions as previously described (4) . At our institution the coefficients of variation (CV) for FM and LBM are 2.9% and 1.4% respectively (30) .
Whole body protein turnover: Whole body protein turnover was assessed using a primed constant infusion of l-[ 13 C] leucine as previously described (11, 16, 53 Calculation of whole body protein turnover: Rates of whole body protein turnover were calculated using the reciprocal pool method as previously described (37) transamination, is used as a surrogate marker of true intracellular leucine enrichment as intracellular and serum levels rapidly equilibrate (37) . As leucine represents 8% of total body protein, or 590 µmol leucine represents 1 gram of protein, rates of protein turnover may be estimated using these constants (27) . The CVs for leucine Ra, Lox and LIP at our institution, based on 7 subjects studied on two occasions, are 3.5%, 6.1% and 3.5% respectively.
Indirect calorimetry: O 2 consumption (VO 2 ) and CO 2 production (VCO 2 ) were measured with the Deltatrac metabolic monitor as described above. Resting energy expenditure (REE) and substrate oxidation rates were calculated using the equations of Ferrannini (8) . The mean dayto-day intra-subject CV for REE at our institution is approximately 4% (14, 29) and fat oxidation approximately 15% (unpublished data).
Analytical methods: KIC was extracted from plasma as described by Nissen et al (28) . KIC enrichment was measured as the butyldimethylsilyl derivative by gas chromatography (model Chicago, Illinois, USA). Results are expressed as mean ± standard error unless otherwise stated. Categorical variables were assessed using a chi-square test. Continuous variables were assessed using unpaired or paired t-tests as appropriate. When data were not normally distributed (changes in body composition with restoration of eucortisolemia), they were logtransformed prior to statistical analysis, however means are presented in the text nontransformed. Simple and multiple regression analyses were performed to examine the relationship between variables. Correction of whole body leucine turnover for the impact of differences in body composition was undertaken by analysis of covariance (ANCOVA), rather than simple division by LBM, as this avoids any statistical bias arising from differences in body composition between the groups (35, 40, 42) .
RESULTS
Cross-sectional study
Subject characteristics
There were no significant differences in gender distribution, age, weight and body mass index between the groups of normal subjects and subjects with Cushing's syndrome (Table 1) .
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Body Composition
A detailed description of whole and regional body composition in the two groups has previously been reported (3). Percentage FM was significantly greater (p=0.002) and LBM (p=0.002) and BMC (p=0.002) lower in subjects with Cushing's syndrome (Table 1) . Truncal fat (p=0.0002) was significantly greater and lean arm and leg mass significantly lower (p<0.0005 for both) in subjects with Cushing's syndrome (Table 1) .
Whole body leucine turnover
LBM was positively correlated with all 3 indices of whole body leucine turnover in normal subjects and subjects with Cushing's syndrome ( Table 2 ). The correlation between leucine turnover and LBM was stronger in normal subjects than in subjects with Cushing's syndrome (Table 2) . After correction for LBM, leucine Ra and Lox were significantly greater in subjects with Cushing's syndrome than in normal subjects; LIP was also higher but the difference did not reach statistical significance (Table 3 and Figure 1 ). If indices of whole body leucine turnover were unadjusted (Table 3 and Figure 1 ) or expressed per kg body weight (data not shown), no significant differences in any of the indices of leucine metabolism between the groups were apparent.
In subjects with Cushing's syndrome, FM was significantly positively correlated with leucine Ra and LIP, but not Lox ( Table 2 ). The correlations between FM and leucine turnover in normal subjects were not statistically significant (Table 2) . When FM was included as a covariate with LBM, Lox was significantly elevated in subjects with Cushing's syndrome, while leucine Ra and LIP were not significantly different (Table 3 and Figure 1 ). Age and 24-Page 9 of 31 h urinary free cortisol were not significantly correlated with indices of whole body leucine turnover (Table 2) .
A multiple regression analysis was performed to determine the independent effects of LBM, FM and glucocorticoid excess (Cushing's syndrome defined as either present or absent) on whole body leucine turnover (Table 4) . LBM was an independent determinant of all 3 indices of whole body leucine turnover. FM was a significant independent determinant of leucine Ra and LIP, but not Lox. Cushing's syndrome was an independent determinant of Lox, but not leucine Ra or LIP.
Longitudinal study
Subject characteristics
Ten subjects were restudied after successful treatment of Cushing's syndrome. Subjects had been eucortisolemic for an estimated 7.6±1.3 months. At the time of retesting 5 subjects were on no glucocorticoid replacement with a mean 24-h urinary free cortisol of 139±41 nmol/d.
Five subjects were receiving physiologic glucocorticoid replacement (prednisone 2.5 to 5 mg/d).
Body composition
Following successful treatment of Cushing's syndrome, mean weight fell by 4.2±3.2 kg, however the change was not statistically significant (p=0.23). There were no significant changes in absolute FM or LBM ( 
Whole body leucine turnover
Changes in leucine metabolism were analyzed after correction for changes in LBM.
Following successful treatment of Cushing's syndrome, Lox fell (p=0.02) and LIP increased (p=0.04) significantly, while leucine Ra did not change (Figure 2 ). There were no significant differences in LBM-adjusted leucine Ra ( +9.3±6.8 µmol/min, p=0.18), Lox ( -3.2±2.1 µmol/min, p=0.13) and LIP ( +12.5±6.6 µmol/min, p=0.07) between treated subjects with Cushing's syndrome and normal subjects.
Indirect calorimetry
There were no significant changes in REE (1431±79 vs 1385±62 were not significantly different after correction for the change in LBM (data not shown).
DISCUSSION
This is the first study assessing postabsorptive whole body protein metabolism in Cushing's syndrome that accounts for the confounding effects of differences in body composition and the first to assess LBM-adjusted changes in protein metabolism after successful treatment.
Percentage FM was significantly greater, and LBM and BMC lower in Cushing's syndrome.
LBM significantly and positively influenced all indices of leucine turnover in both groups. In This study shows that elucidation of the effect of glucocorticoid excess on postabsorptive whole body protein metabolism in Cushing's syndrome requires distinction of the effects of body composition differences from the effects of glucocorticoid excess per se. Differences in LBM account for 60-80% of the explained variability of rates of all 3 indices of leucine turnover (16, 51) and correction of whole body leucine turnover for the size of the LBM is now standard practice. As LBM is markedly reduced in Cushing's syndrome, failure to correct for it in previous studies would have resulted in underestimation of all indices of leucine metabolism (2, 44). Had we failed to correct for LBM we would have come to a similar erroneous conclusion that Lox is normal in Cushing's syndrome (Table 3) .
Glucocorticoid excess increased postabsorptive Lox, independent of differences in both LBM and FM, in Cushing's syndrome (Table 3 and While adipose tissue accounts for 6-12% of whole-body proteolysis (7, 32) , the contribution of adipose tissue to leucine Ra was similar in lean and markedly obese individuals (32) . This
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suggests that the increased leucine Ra in obesity is not because of increased protein breakdown within adipose tissue, but that adipose tissue may influence protein breakdown in lean tissue via an indirect mechanism. Speculation on the relationship between FM and leucine Ra has centered on the possibility that the increased leucine Ra in obesity may arise from reduced sensitivity to insulin. Insulin-induced inhibition of proteolysis is attenuated in obese (25) and insulin-resistant subjects (15, 45) . However, no correlation was found between leucine Ra and insulin sensitivity measured by euglycaemic-hyperinsulinaemic clamp (46) .
Thus, the basis of the relationship between FM and protein breakdown is yet to be clearly defined.
Following treatment of Cushing's syndrome there was a significant fall in percentage FM and an increase in percentage, but not absolute, LBM. Previous studies have reported that while successful control of GC excess in Cushing's syndrome reduces FM, LBM remains subnormal and does not significantly increase (23, 33, 48). We found postabsorptive Lox fell and LIP increased after successful treatment, while leucine Ra was not significantly affected.
Therefore, a greater proportion of amino acids generated from protein breakdown are reincorporated back into protein rather than oxidized. However, Lox was reduced to the level of normal subjects, not significantly below it, which is necessary for protein anabolism. It is possible that we missed a transient reduction in Lox below levels found in normal subjects, as subjects were studied more than 6 months on average after successful treatment. However, a normal rate of protein oxidation would predict a stable, but not increasing, protein mass.
A limitation of the whole body leucine turnover technique is that the results represent the net effect in all tissues and do not provide information on regional contribution to protein turnover. There is major interest in the impact of glucocorticoid excess on skeletal muscle protein metabolism, as limb lean tissue is preferentially lost in Cushing's syndrome (3, 9, 49).
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Although skeletal muscle represents the largest mass of body protein, it only accounts for 30-50% of whole body protein breakdown, oxidation and synthesis (43) . Therefore changes in whole body protein metabolism may not reflect that in skeletal muscle. In contrast to the acute glucocorticoid-induced increase in whole body protein breakdown and oxidation, forearm and lower limb studies have not observed any significant change in skeletal muscle protein metabolism following acute glucocorticoid administration in the postabsorptive state (22, 24, 39) . However, one study reported a reduction in skeletal muscle fractional synthesis rate in subjects on long-term glucocorticoids (12) . The discrepancy between whole body and regional studies may reflect a greater effect of glucocorticoids on non-skeletal protein sources such as the splanchnic bed or the sensitivity or endpoints of the method under conditions of the study. For example, regional studies based on arteriovenous differences in amino acid enrichment do not directly quantify amino acid oxidation, which was increased in the whole body study.
Despite our efforts to correct data for body compositional change, it is not possible to account for all variables that could influence protein metabolism in a cross-sectional study. We have previously reported that the mean extracellular water volume was not significantly different in a subset of the subjects from each group, therefore hydration of the LBM is unlikely to affect results (3). Furthermore, it is unlikely that deficiencies of other hormones significantly influenced results. While subjects were not formally evaluated for GH deficiency, protein oxidation in GH-deficient adults is not significantly different to normal subjects (16) . The one subject with untreated androgen deficiency is unlikely to have markedly confounded results and omission of this subject's data did not influence the findings. The paired longitudinal data, where restoration of eucortisolemia resulted in a reduction in Lox with no change in leucine Ra, corroborate the cross-sectional data showing the independent effect of 
